Bayer to end non-US sales of Essure
The pharmaceutical giant Bayer announced Monday that it would end non-US sales of Essure, a sterilisation implant that in news reports has been linked to major side effects.
"This decision is being taken for commercial reasons," the German group said.
The withdrawal extended a decision taken in May to halt sales of the device in most countries where it was being marketed, it said.
Essure, a non-hormonal coil implant used to sterilise women, has in some women caused chronic pain, perforation of the uterus and fallopian tubes and led to hysterectomies, news reports say.
In its statement in French, Bayer insisted "this decision is not linked to any problem of safety or quality of the product... the safety and effectiveness of Essure is supported by more than 10 years of scientific research and real-life clinical settings."
It added: "Bayer will continue to market the Essure medical device in the United States, where the FDA [Food and Drug Administration] recently assessed this device and concluded that the method had a favourable benefit-risk ratio."
Read the full article here.